BackGreat Novel Therapeutics Biotech & Medicals Overview

Great Novel Therapeutics Biotech & Medicals Profit Margin

Latest profit margin for Great Novel Therapeutics Biotech & Medicals: -2496.14% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-1048.33%
↑ 85.42% YoY

As of Jun 2026

Annual Profit Margin (TTM)

-2496.14%
↑ 16.86% YoY

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Great Novel Therapeutics Biotech & Medicals (7427.TWO) FAQ

Great Novel Therapeutics Biotech & Medicals's profit margin stands at -2496.14% as of June 2026. That compares with -3002.47% in the prior-year period — up 16.9% year over year. That is below the Healthcare sector average of 17.63%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Great Novel Therapeutics Biotech & Medicals reported -2496.14% in profit margin versus -3002.47% a year earlier — a 16.9% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Great Novel Therapeutics Biotech & Medicals sits lower the Healthcare benchmark (17.63%) with a profit margin of -2496.14%. That is roughly 14259.7% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -2496.14% for Great Novel Therapeutics Biotech & Medicals means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Great Novel Therapeutics Biotech & Medicals's profit margin evolved across reporting periods, while the comparison chart places 7427.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.